Search for content, post, videos

Popular posts – Nordic Life Science

AstraZeneca scientist

These are some of the most popular articles on this year.

2020 has been a very challenging year and a large part of our industry news on our site have consisted of Nordic efforts to handle, treat and prevent COVID-19, but we have also seen Nordic life science companies making progress and announcing positive updates.


A population-based study of the early spread of the new coronavirus in Iceland

COVID-19 sampling deCODE

Scientists at deCODE genetics and Iceland’s Directorate of Health and the National University Hospital has published a population-based study of the early spread of the SARS-Cov-2 virus, causing COVID-19 disease, in Iceland.


Continue reading the article



Exclusive interview: Mikael Dolsten, Chief Scientific Officer, Pfizer

Mikael Dolsten

The days are busy for Sweden’s Mikael Dolsten. As head of Pfizer’s R&D he is at the scientific forefront of the fight against the COVID-19 pandemic. If everything goes well, the company could begin manufacturing its vaccine candidate by the end of the year.

Continue reading the interview



Different COVID-19 strategies in the Nordic countries

Sweden Norway Finland Denmark

Given the similarity of the Nordic societies, it is interesting to note how differently some of them have reacted to the current COVID-19 crisis, writes Johan Strang, Associate Professor at the Centre for Nordic Studies, the University of Helsinki.

Continue reading the article



AstraZeneca’s vaccine met primary efficacy endpoint

AstraZeneca scientist

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalizations or severe cases of the disease were reported in participants receiving the vaccine.

Continue reading the article



Lund-based research organizations form consortium


A consortium of private and public organisations announces a collaboration that aims to assemble and utilize a platform for rapid response to the current SARS-CoV-2 pandemic as well as future threats.

Continue reading the article



COVID-19: Industry impact so far

Helena Strigård and Per Spindler

NLS has asked industry organizations in all the Nordic countries about the situation and the impact of the COVID-19 pandemic.

Continue reading the interviews



BerGenBio’s Bemcentinib – potential treatment for COVID-19

Richard Godfrey

BerGenBio has announced that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK national multi-centre randomized Phase II clinical trial initiative.

Continue reading the article



Danish coronavirus vaccine passes test in mice

Ali Salanti

A vaccine against COVID-19, developed by researchers from the University of Copenhagen, has been tested in mice and shows promising results.

Continue reading the article



Swedish researchers have identified nanobodies that may prevent COVID-19 infection

Leo Ben and Gerald

Researchers at Karolinska Institutet have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.

Continue reading the article



Vaccibody enters agreement with Genentech and accelerates R&D programs

Agnete B Fredriksen and Michael Engsig

Vaccibody has announced that it has entered into an exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers.

Continue reading the article



10X Genomics acquires Swedish Cartana

Malte Kühnemund

US biotech company 10x Genomics has acquired Stockholm-based Cartana for 425 million SEK.

Continue reading the article



Novo Nordisk to acquire Emisphere Technologies for USD 1.8 billion

Mads Krogsgaard Thomsen

Novo Nordisk has entered into a definitive agreement to acquire Emisphere Technologies, a drug delivery company with technologies such as the Eligen SNAC technology, that enable oral formulations of therapeutics.

Continue reading the article



Alvotech enters biosimilar partnership in China

Robert Wessman

Alvotech and Alvotech & CCHT Biopharmaceutical, which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered with Yangtze River Pharmaceutical Group to form an exclusive strategic partnership for the commercialization of eight biosimilar medicines in China.

Continue reading the article



Nanoform launches technology for biologics


Nanoform Finland has announced a technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.

Continue reading the article